SCHEMBL2371385

SCHEMBL2371385

COc1cc(F)ccc1-c1ccnc(N)c1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DYRK1A Q13627 4/20 0.53
AAK1 Q2M2I8 1/20 0.50
CDC7 O00311 1/20 0.46
ALOX5AP P20292 2/20 0.46
FEN1 P39748 2/20 0.46
CDK2 P24941 4/20 0.46
GSK3B P49841 4/20 0.46
CDK9 P50750 4/20 0.46
CDK1 P06493 3/20 0.46
CDK3 Q00526 3/20 0.46
CDK5 Q00535 3/20 0.46
GSK3A P49840 3/20 0.46
CCNT1 O60563 2/20 0.46
CCNB1 P14635 2/20 0.46
CCNE1 P24864 2/20 0.46
CCNA1 P78396 2/20 0.46
CDK5R1 Q15078 2/20 0.46
SYK P43405 1/20 0.45
PSEN1 P49768 1/20 0.45
PSEN2 P49810 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30507450 1.00 DYRK1A (0.53) DYRK1AAAK1CDC7ALOX5APFEN1
SCHEMBL16371252 0.84 DYRK1A (0.55) DYRK1AAAK1CDC7ALOX5APFEN1
SCHEMBL3361169 0.83 DYRK1A (0.60) DYRK1AAAK1ALOX5APFEN1GSK3B
SCHEMBL2370541 0.82 AAK1 (0.49) AAK1CDK2GSK3BCDK9CDK1
SCHEMBL16107760 0.80 KCNH2 (0.44) DYRK1AALOX5APFEN1CDK2GSK3B
SCHEMBL11425087 0.79 CYP11B1 (0.55) CDK2GSK3BSYKKCNH2GRM5
SCHEMBL12485951 0.78 CDK9 (0.51) CDK2GSK3BCDK9CDK1CDK3
SCHEMBL3363019 0.76 PIK3C3 (0.47) DYRK1AALOX5APFEN1
SCHEMBL21859672 0.76 ABL1 (0.62) DYRK1ANOS3NOS1NOS2KCNH2
SCHEMBL29655054 0.76 TDP1 (0.47) ALOX5APFEN1SYKKCNH2FYN

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-112010844-B Preparation method and application of N- (pyrimidine-2-yl) coumarin-7-amine derivative as protein kinase inhibitor 中国药科大学 2023-07-25 CN disclosed
WO-2023020209-A1 UREA COMPOUND CONTAINING 2-HETEROAROMATIC RING SUBSTITUTION, PREPARATION METHOD THEREFOR AND USE THEREOF 中国科学院上海药物研究所 2023-02-23 WO disclosed
CN-112010844-A Preparation method and application of N- (pyrimidine-2-yl) coumarin-7-amine derivative as protein kinase inhibitor 中国药科大学 2020-12-01 CN disclosed
US-20150272947-A1 INHIBITORS OF PROTEIN KINASES ASTRAZENECA AB (SE) 2015-10-01 US disclosed
US-20150272947-A1 INHIBITORS OF PROTEIN KINASES ASTRAZENECA AB (SE) 2015-10-01 US disclosed
US-20150272947-A1 INHIBITORS OF PROTEIN KINASES ASTRAZENECA AB (SE) 2015-10-01 US disclosed
US-9067888-B2 Inhibitors of protein kinases ASTRAZENECA AB (SE) 2015-06-30 US disclosed
US-9067888-B2 Inhibitors of protein kinases ASTRAZENECA AB (SE) 2015-06-30 US disclosed
US-9067888-B2 Inhibitors of protein kinases ASTRAZENECA AB (SE) 2015-06-30 US disclosed
US-20130345233-A1 INHIBITORS OF PROTEIN KINASES INGENIUM PHARMACEUTICALS GMBH (DE) 2013-12-26 US disclosed
US-8518948-B2 Inhibitors of protein kinases INGENIUM PHARMACEUTICALS GMBH (DE) 2013-08-27 US disclosed
US-8518948-B2 Inhibitors of protein kinases INGENIUM PHARMACEUTICALS GMBH (DE) 2013-08-27 US disclosed
EP-2545037-A1 INHIBITORS OF PROTEIN KINASES Ingenium Pharmaceuticals GmbH (DE) 2013-01-16 EP disclosed
US-20110224225-A1 Inhibitors of protein kinases ASTRAZENECA AB (SE) 2011-09-15 US disclosed
US-20110224225-A1 Inhibitors of protein kinases ASTRAZENECA AB (SE) 2011-09-15 US disclosed
US-20110224225-A1 Inhibitors of protein kinases ASTRAZENECA AB (SE) 2011-09-15 US disclosed
WO-2011110612-A1 INHIBITORS OF PROTEIN KINASES INGENIUM PHARMACEUTICALS GMBH (DE) 2011-09-15 WO disclosed
WO-2011110612-A1 INHIBITORS OF PROTEIN KINASES INGENIUM PHARMACEUTICALS GMBH (DE) 2011-09-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130345233-A1 INHIBITORS OF PROTEIN KINASES CDK1, CDK2, CDK3 DYRK1A 494/4885AAK1 136/4885CDC7 114/4885
US-20150272947-A1 INHIBITORS OF PROTEIN KINASES CDK1, CDK2, CDK3 DYRK1A 494/4885AAK1 136/4885CDC7 114/4885
US-20110224225-A1 Inhibitors of protein kinases CDK1, CDK2, CDK3 DYRK1A 494/4885AAK1 136/4885CDC7 114/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.